Egetis Therapeutics AB (publ) (STO:EGTX)
Sweden · Delayed Price · Currency is SEK 5.17
+0.05 (0.98%)
Feb 10, 2026, 5:29 PM CET
Egetis Therapeutics AB Revenue
Egetis Therapeutics AB had revenue of 17.40M SEK in the quarter ending September 30, 2025, with 85.11% growth. This brings the company's revenue in the last twelve months to 55.40M, down -18.41% year-over-year. In the year 2024, Egetis Therapeutics AB had annual revenue of 46.10M, down -19.97%.
Revenue (ttm)
55.40M
Revenue Growth
-18.41%
P/S Ratio
36.52
Revenue / Employee
1.39M
Employees
40
Market Cap
2.02B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 46.10M | -11.50M | -19.97% |
| Dec 31, 2023 | 57.60M | 35.00M | 154.87% |
| Dec 31, 2022 | 22.60M | -15.60M | -40.84% |
| Dec 31, 2021 | 38.20M | -2.46M | -6.05% |
| Dec 31, 2020 | 40.66M | -41.90M | -50.75% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Saniona AB | 743.21M |
| BioInvent International AB | 244.85M |
| Hansa Biopharma AB | 178.61M |
| Genovis AB (publ.) | 117.66M |
| Oncopeptides AB | 62.47M |
| Vicore Pharma Holding AB | 8.50M |
| Xspray Pharma AB | 3.81M |
| Flerie AB | 2.80M |